The LANCE® Ultra Human TAU Detection Kit is designed for detection and quantitation of human Tau in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|TRF1271C||500 Assay Points||796.00 USD|
|TRF1271M||10,000 Assay Points||10600.00 USD|
You successfully added item(s) to your cart
The LANCE® Ultra Human TAU Detection Kit is designed for detection and quantitation of human tau in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Microtubule-associated Protein Tau (TAU) is a neuronal protein that binds to axonal microtubules and has roles in the assembly of microtubules, cytoskeletal structure, and axonal transport. Six isoforms of Tau have been described, ranging from 352 to 441 residues, all originating from the alternative splicing of one gene designated MAPT. Tau interacts with tubulin to stabilize the microtubules, but its phosphorylation blocks this association, resulting in disruption of microtubule organization. In humans, hyperphosphorylated Tau can self-assemble into very insoluble aggregates (paired helical filaments) leading to various pathologies. Tauopathy is the name given to diseases associated with Tau accumulation, among which Alzheimer’s disease (AD) is one of the best known. Tau is a biochemical marker for this neurodegenerative disease as an increase of Tau in cerebrospinal fluid is observed in most patients with AD.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Assay Target Class||Peptide|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System|
|Unit Size||500 Assay Points|
|Resource Type||File Name||File Format|
|Brochure||LANCE product listing||PDF 77 KB|
|Application Note||High Throughput Quantitation of Cytokine Biomarkers using LANCE Ultra TR-FRET Assays||PDF 1 MB|
|Application Note||Quantifying Bcl-2 Expression Levels in Human Cells with LANCE Ultra TR-FRET||PDF 3 MB|
|Manual||LANCE Ultra Human Tau Detection Kit TRF1271||PDF 485 KB|
|Flyer||LANCE Ultra Biomarker Detection Kits||PDF 585 KB|